BRPI0908474A2 - métodos de uso de cromatografia de troca de íon e de filtração de gel para purificação de vírus causador da catapora - Google Patents

métodos de uso de cromatografia de troca de íon e de filtração de gel para purificação de vírus causador da catapora

Info

Publication number
BRPI0908474A2
BRPI0908474A2 BRPI0908474A BRPI0908474A BRPI0908474A2 BR PI0908474 A2 BRPI0908474 A2 BR PI0908474A2 BR PI0908474 A BRPI0908474 A BR PI0908474A BR PI0908474 A BRPI0908474 A BR PI0908474A BR PI0908474 A2 BRPI0908474 A2 BR PI0908474A2
Authority
BR
Brazil
Prior art keywords
methods
ion exchange
exchange chromatography
gel filtration
pox virus
Prior art date
Application number
BRPI0908474A
Other languages
English (en)
Inventor
Yelin Xiong
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40956580&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0908474(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Publication of BRPI0908474A2 publication Critical patent/BRPI0908474A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24051—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
BRPI0908474A 2008-02-12 2009-02-12 métodos de uso de cromatografia de troca de íon e de filtração de gel para purificação de vírus causador da catapora BRPI0908474A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6548408P 2008-02-12 2008-02-12
PCT/CA2009/000141 WO2009100521A1 (en) 2008-02-12 2009-02-12 Methods using ion exchange and gel filtration chromatography for poxvirus purification

Publications (1)

Publication Number Publication Date
BRPI0908474A2 true BRPI0908474A2 (pt) 2016-07-26

Family

ID=40956580

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0908474A BRPI0908474A2 (pt) 2008-02-12 2009-02-12 métodos de uso de cromatografia de troca de íon e de filtração de gel para purificação de vírus causador da catapora

Country Status (11)

Country Link
US (1) US20110165645A1 (pt)
EP (1) EP2240573A4 (pt)
JP (2) JP2011511640A (pt)
KR (1) KR20100113159A (pt)
CN (1) CN102257134B (pt)
AU (1) AU2009214768B2 (pt)
BR (1) BRPI0908474A2 (pt)
CA (1) CA2713891A1 (pt)
IL (1) IL207460A0 (pt)
MX (1) MX2010008970A (pt)
WO (1) WO2009100521A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG176554A1 (en) * 2009-05-12 2012-01-30 Transgene Sa Method for orthopoxvirus production and purification
US9644187B2 (en) * 2010-04-14 2017-05-09 Emd Millipore Corporation Methods of producing high titer, high purity virus stocks and methods of use thereof
US10087423B2 (en) 2010-07-20 2018-10-02 Bavarian Nordic A/S Method for harvesting expression products
EP2598223B1 (en) 2010-07-30 2022-04-06 EMD Millipore Corporation Chromatography media and method
WO2013154928A1 (en) * 2012-04-08 2013-10-17 Kapre Subhash V Systems and methods of virus propagation in cell culture for vaccine manufacture
CN105316296A (zh) * 2014-06-13 2016-02-10 亚宝药业太原制药有限公司 一种纯化腺病毒颗粒的方法
PL3169341T3 (pl) 2014-07-16 2019-12-31 Transgene Sa Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej
CN106794389A (zh) 2014-09-02 2017-05-31 Emd密理博公司 具有纳米原纤化表面特征的高表面积纤维介质
KR102632022B1 (ko) * 2014-12-05 2024-01-31 후지필름 가부시키가이샤 Tim 단백질 결합 담체, 당해 담체를 사용한 세포외막소포 및 바이러스의 취득 방법, 제거 방법, 검출 방법 그리고 당해 담체를 포함하는 키트
CN107001410A (zh) 2014-12-08 2017-08-01 Emd密理博公司 混合床离子交换吸附剂
CA2975432A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
DK3307878T3 (da) * 2015-06-10 2021-10-11 Us Health Fremgangsmåder til fremstilling og oprensning af nukleinsyreholdige sammensætninger
CN105219741A (zh) * 2015-08-24 2016-01-06 深圳市百恩维生物科技有限公司 一种大规模获得高纯度、高活性慢病毒的工艺方法
US20190134190A1 (en) 2016-05-04 2019-05-09 Transgene Sa Combination therapy with cpg tlr9 ligand
MX2019000882A (es) * 2016-07-21 2019-08-12 Spark Therapeutics Inc Metodos de alta recuperacion escalables para una alta produccion de vector viral adenoasociado recombinante (raav) y vectores virales adenoasociados recombinantes (raav) producidos de este modo.
MX2019002495A (es) * 2016-09-01 2020-02-17 Takeda Vaccines Inc Metodos para producir virus para la produccion de vacunas.
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
WO2018091680A1 (en) 2016-11-18 2018-05-24 Transgene Sa Cowpox-based oncolytic vectors
CN106754346A (zh) * 2016-12-12 2017-05-31 厦门华厦学院 Dna微提取系统及dna微提取方法
CA3045228C (en) 2016-12-28 2024-01-02 Transgene Sa Oncolytic viruses and therapeutic molecules
WO2018211419A1 (en) 2017-05-15 2018-11-22 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
KR20200003921A (ko) 2017-05-15 2020-01-10 얀센 백신스 앤드 프리벤션 비.브이. 안정한 바이러스-함유 조성물
JP7334124B2 (ja) 2017-06-21 2023-08-28 トランジェーヌ 個別化ワクチン
CN107485891B (zh) * 2017-07-20 2020-04-21 上海药明生物技术有限公司 改良的层析装置及其用于连续流层析的方法
WO2019020543A1 (en) 2017-07-28 2019-01-31 Transgene Sa ONCOLYTIC VIRUSES EXPRESSING AGENTS TARGETING METABOLIC IMMUNE MODULATORS
CN107603959A (zh) * 2017-08-30 2018-01-19 四川大学 提高缓冲液盐离子浓度纯化病毒的方法
CN108159411A (zh) * 2018-01-11 2018-06-15 江苏中慧元通生物科技有限公司 一种流感病毒亚单位疫苗纯化方法及其应用
WO2020011754A1 (en) 2018-07-09 2020-01-16 Transgene Chimeric vaccinia viruses
EP3617230A1 (en) 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
EP3847246A1 (en) 2018-09-06 2021-07-14 Bavarian Nordic A/S Storage improved poxvirus compositions
BR112021012630A2 (pt) 2018-12-28 2022-12-13 Transgene Sa Poxvírus modificado, método para produzir o poxvírus modificado e composição
CN110241093A (zh) * 2019-06-17 2019-09-17 深圳源兴基因技术有限公司 一种重组痘病毒的纯化方法
CN112143693B (zh) 2019-06-28 2024-12-27 杭州康万达医药科技有限公司 一种生产病毒的方法及收获液组合物
EP3842065A1 (en) 2019-12-23 2021-06-30 Transgene Process for designing a recombinant poxvirus for a therapeutic vaccine
EP4117722A1 (en) 2020-03-12 2023-01-18 Bavarian Nordic A/S Compositions improving poxvirus stability
CN111876392A (zh) * 2020-06-30 2020-11-03 恒瑞源正（上海）生物科技有限公司 一种大规模快速生产病毒载体的方法
TW202217002A (zh) 2020-07-13 2022-05-01 法商傳斯堅公司 免疫抑制之治療
WO2022148736A1 (en) 2021-01-05 2022-07-14 Transgene Vectorization of muc1 t cell engager
WO2023025899A2 (en) 2021-08-26 2023-03-02 Transgene Delivery system for targeting genes of the interferon pathway
TW202321458A (zh) 2021-09-22 2023-06-01 瑞典商生物創新國際公司 新穎抗體組合及其用途
CN114544815B (zh) * 2022-03-01 2023-10-27 中牧实业股份有限公司 一种山羊痘病毒的定量检测方法
WO2023213764A1 (en) 2022-05-02 2023-11-09 Transgene Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
WO2023213763A1 (en) 2022-05-02 2023-11-09 Transgene Poxvirus encoding a binding agent comprising an anti- pd-l1 sdab
EP4547273A1 (en) 2022-06-29 2025-05-07 Bavarian Nordic A/S Recombinant modified sarna (vrp) and vaccinia virus ankara (mva) prime-boost regimen
CN119604618A (zh) 2022-06-29 2025-03-11 巴法里安诺迪克有限公司 爱泼斯坦-巴尔病毒疫苗
JP2025523573A (ja) 2022-07-01 2025-07-23 トランジェーヌ サーファクタントタンパク質－ｄとｔｎｆｓｆのメンバーを含んでなる融合タンパク質
US20260049291A1 (en) 2022-08-18 2026-02-19 Transgene Chimeric poxviruses
CN115261341B (zh) * 2022-09-05 2024-03-22 东曜药业有限公司 一种澄清溶瘤痘苗病毒收获液的方法
CN115873810B (zh) * 2022-12-26 2024-02-09 苏州良辰生物医药科技有限公司 一种鼠白血病病毒的纯化方法
WO2026041811A1 (en) 2024-08-23 2026-02-26 Transgene Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US5364773A (en) 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
CA1341245C (en) 1988-01-12 2001-06-05 F. Hoffmann-La Roche Ag Recombinant vaccinia virus mva
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
IT1248075B (it) * 1991-06-18 1995-01-05 Sclavo Spa Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono.
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US5990091A (en) 1997-03-12 1999-11-23 Virogenetics Corporation Vectors having enhanced expression, and methods of making and uses thereof
US6410300B1 (en) * 1998-01-12 2002-06-25 The University Of North Carolina At Chapel Hill Methods and formulations for mediating adeno-associated virus (AAV) attachment and infection and methods for purifying AAV
WO1999061643A1 (en) * 1998-05-27 1999-12-02 University Of Florida Method of preparing recombinant adeno-associated virus compositions by using an iodixananol gradient
ES2247404T3 (es) * 2001-12-20 2006-03-01 Bavarian Nordic A/S Metodo para la recuperacion y purificacion de poxvirus de celulas infectadas.
DE10232828A1 (de) * 2002-07-19 2004-02-05 Goldschmidt Ag Verwendung von Antioxidantien in strahlenhärtbaren Beschichtungsmassen für die Herstellung von abhäsiven Beschichtungen
AU2004249199B2 (en) * 2003-06-18 2008-07-24 Onyx Pharmaceuticals, Inc. Method for purifying virus
AU2005214090B2 (en) * 2004-02-23 2008-09-11 Crucell Holland B.V. Virus purification methods
WO2006011580A1 (ja) * 2004-07-27 2006-02-02 Genomidea, Inc. ウイルスエンベロープの精製方法
US7901921B2 (en) * 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods

Also Published As

Publication number Publication date
IL207460A0 (en) 2010-12-30
US20110165645A1 (en) 2011-07-07
WO2009100521A1 (en) 2009-08-20
JP5898261B2 (ja) 2016-04-06
MX2010008970A (es) 2011-05-30
KR20100113159A (ko) 2010-10-20
AU2009214768A1 (en) 2009-08-20
AU2009214768B2 (en) 2015-01-22
CN102257134A (zh) 2011-11-23
EP2240573A1 (en) 2010-10-20
CA2713891A1 (en) 2009-08-20
EP2240573A4 (en) 2011-08-31
JP2014138622A (ja) 2014-07-31
JP2011511640A (ja) 2011-04-14
CN102257134B (zh) 2014-03-05

Similar Documents

Publication Publication Date Title
BRPI0908474A2 (pt) métodos de uso de cromatografia de troca de íon e de filtração de gel para purificação de vírus causador da catapora
EP2134360A4 (en) CLEANING VIRUSUAL PARTICLES
BRPI0812206A2 (pt) Métodos para melhorar o desempenho de proteínas
BR112013013668A2 (pt) moduladores 7-deazapurina de histona metiltransferase, e métodos de uso dos mesmos
EP2226331A4 (en) PROCESS FOR CLEANING PROTEINS
BR112012004088A2 (pt) processos para dissociação de moléculas alvo e sistema para uso no mesmo
BRPI0810740A2 (pt) Sistema de conversão de polarização e método para projeção esteroscópica
BRPI0915928A2 (pt) composições e métodos de uso para anticorpos terapêuticos
BRPI0921433A2 (pt) uso de anticorpos anti-cs1 para o tratamento de linfomas raros
IL216222A (en) Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
DK2526114T3 (da) Kromatografisk fremgangsmåde til oprensning af FC-indeholdende proteiner
DK2848625T3 (da) Fremgangsmåder til fjernelse af en kontaminant under anvendelse af ion bytningsmembrankromatografi med forskydning af naturligt forekommende proteiner
BRPI1013347A2 (pt) derivados de quinazolina modulantes da quinase jak e métodos para o uso dos mesmos
BRPI0910449A2 (pt) Processo para purificação de álcool de fermentação
BRPI0919252A2 (pt) Métodos para cultivar células, propagação e purificação de vírus
BRPI0915825A2 (pt) proteínas de ligação à prostaglandina e2 usos das mesmas
BRPI0919250A2 (pt) métodos para a purificação de vírus
EP2279040A4 (en) CATIONIC MICROCAPSE PARTICLES
EP2338840A4 (en) FILTRATION AND COMPOSITE DESALINATION EQUIPMENT
DK2061803T4 (da) Fremgangsmåde til oprensning af fc-holdige proteiner
BRPI0921546A2 (pt) Compostos de arilazol-2-il cianoetilamina enriquecidos enantiomericamente, método para fabricação e método de uso dos mesmos
BRPI0908412A2 (pt) método para purificar álcool de fermentação
BR112014028396A2 (pt) processo de isolamento/purificação de célula de tumor e métodos para uso da mesma
BRPI0817257A2 (pt) Anticorpos moniclonais para vírus sincital respiratório e usos dos mesmos
DK2361388T3 (da) Fremgangsmåder til karakterisering af molekyler

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]